Acquisition of exclusive manufacturing and marketing rights for DOTATOC

Garching (ots) -

- In-licensing of superior DOTA-Tyr3-octreotide
- Pharmaceutical development for treatment of NETs
- Excellent pharmacokinetic properties

ITM Isotope Technologies Munich AG (ITM) today announced that it
has entered into an exclusive licensing agreement with Progenics
Pharmaceuticals Inc. for pharmaceutical development and
commercialization of radiolabeled DOTA-conjugated somatostatin
analogue DOTA-[Tyr3]-octreotide (DOTATOC known as Edotreotide) for
human oncology therapeutic use. Radiolabeled DOTATOC is a superior
agent for safe and highly effective radionuclide therapy of
somatostatin receptor positive tumors which offers excellent
pharmacokinetic properties and highest affinity to somatostatin
receptor subtypes 2 and 5.

Scope of license agreement

The sublicense granted by Progenics Pharmaceuticals Inc. covers
exclusive worldwide manufacturing and marketing rights of DOTATOC and
certain radiolabeled DOTATOC for human oncology therapeutic use
except the countries Albania, Algeria, Bahrain, Bulgaria, Cyprus,
Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi
Arabia, Syria, Turkey and United Arab Emirates. Further terms of the
agreement were not disclosed.

Pharmaceutical development

ITM affiliate ITG Isotope Technologies Garching GmbH will develop
radiolabeled DOTATOC for treatment of metastatic neuroendocrine
tumors. In addition, DOTATOC as precursor is now available and will
be distributed in GMP quality in cooperation with a leading supplier
of advanced chemicals for nuclear medicine.

About DOTATOC

DOTATOC or Edotreotide is a superior synthetic somatostatin analog
which binds perfectly to somatostatin receptors predominantly
overexpressed in neuroendocrine tumors (NETs). NETs are rare kind of
tumors which arise from neuroendocrine cells and may occur in
different parts of the body.

DOTA-chelated peptide Edotreotide exhibits excellent
pharmacokinetic properties and can be efficiently radiolabeled with
medical radionuclides. Its excellent therapeutic properties have been
successfully started in various clinical trials.

About ITM Isotope Technologies Munich AG

The itm Group is the leading company for the development,
production and worldwide distribution of highly effective
radionuclides for diagnosis and therapy as well as radionuclide-based
medical devices. Its commitment to shaping the future of theranostics
is built on robust platform technologies and innovative new
generation radioisotopes which assure safety, performance and
security of supply!

Contacts
Christopher Morin
Manager Marketing & Corporate Communications
Phone: +49 89 289 13915
Mail: Christopher.Morin@itg-garching.de

Steffen Schuster
CEO
Phone: +49 89 289 13970
Mail : Steffen.Schuster@itm.ag

ITM Isotope Technologies Munich AG
Aufsichtsratsvorsitzender - Udo J. Vetter, Vorstandsvorsitzender -
Steffen Schuster, Sitz der Gesellschaft - Lichtenbergstr. 1, 85748
Garching - HG München - HRB 154944